Shopping Cart
Remove All
Your shopping cart is currently empty
Tanezumab
😃Good
Catalog No. T78282Cas No. 880266-57-9
Tanezumab (RN-624) is a humanised monoclonal antibody targeting NGF (nerve growth factor). It inhibits the sensitisation and conduction of peripheral pain fibres by blocking the interaction between NGF and the p75 and TrkA receptors, thereby treating various acute and chronic pain conditions, including osteoarthritis, knee arthritis, and neuropathic pain.
Tanezumab
Tanezumab
😃Good
Catalog No. T78282Cas No. 880266-57-9
Tanezumab (RN-624) is a humanised monoclonal antibody targeting NGF (nerve growth factor). It inhibits the sensitisation and conduction of peripheral pain fibres by blocking the interaction between NGF and the p75 and TrkA receptors, thereby treating various acute and chronic pain conditions, including osteoarthritis, knee arthritis, and neuropathic pain.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $172 | - | In Stock | |
| 5 mg | $433 | - | In Stock | |
| 10 mg | $695 | - | In Stock | |
| 25 mg | $1,060 | - | In Stock | |
| 50 mg | $1,430 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:95.9% (SDS-PAGE); 95.3% (SEC-HPLC)
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Tanezumab (RN-624) is a humanised monoclonal antibody targeting NGF (nerve growth factor). It inhibits the sensitisation and conduction of peripheral pain fibres by blocking the interaction between NGF and the p75 and TrkA receptors, thereby treating various acute and chronic pain conditions, including osteoarthritis, knee arthritis, and neuropathic pain. |
| In vitro | Methods: To evaluate the effect of Tanezumab on cell migration, MiaPaCa-2 and CFPAC-1 cells were treated with 100 ng/mL of the drug and incubated for 48 hours before performing a cell migration assay. Results: Tanezumab significantly inhibited the migration of MiaPaCa-2 and CFPAC-1 cells [3]. |
| In vivo | Methods: To evaluate the in vivo efficacy of Tanezumab, MiaPaCa-2 xenograft mouse models were administered 10 mg/kg subcutaneously once daily for 8 weeks. Results: Tanezumab reduced tumor volume and invasive nerve diameter, and alleviated hindlimb dysfunction [3]. |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | NGF/bNGF |
| Molecular Weight | 145.43 kDa |
| Cas No. | 880266-57-9 |
| Isotype | Human IgG2 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Tanezumab | purchase Tanezumab | Tanezumab cost | order Tanezumab | Tanezumab in vivo | Tanezumab in vitro | Tanezumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.